Evidence map›Paper›PMID 29505315›Full record

ReviewCell adhesion & migration2018

A putative role for Discoidin Domain Receptor 1 in cancer chemoresistance.

Chiara Ambrogio, Elodie Darbo, Sam W Lee, David Santamaría

Open access · goldAbstract readReview
In one paragraph

Review in Cell adhesion & migration, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Complex roles of discoidin domain receptor tyrosine kinases in cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021
    Review
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Chiara Ambrogioa Department of Medical Oncology , Dana-Farber Cancer Institute , Boston , MA , USA.ORCID 0000-0003-4122-701X
Elodie Darbob University of Bordeaux , INSERM U1218, ACTION Laboratory, Centre de Bioinformatique de Bordeaux (CBiB) , Bordeaux , France.
Sam W Leec Cutaneous Biology Research Center , Massachusetts General Hospital and Harvard Medical School , Charlestown , MA , USA.
David Santamaríad University of Bordeaux , INSERM U1218, ACTION Laboratory, IECB , Pessac , France.
Université de Bordeaux · FRDana-Farber Cancer Institute · USHarvard University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Discoidin Domain Receptor 1 (DDR1) receptor tyrosine kinase performs pleiotropic functions in the control of cell adhesion, proliferation, survival, migration, and invasion. Aberrant DDR1 function as a consequence of either mutations or increased expression has been associated with various human diseases including cancer. Pharmacological inhibition of DDR1 results in significant therapeutic benefit in several pre-clinical cancer models. Here, we discuss the potential implication of DDR1-dependent pro-survival functions in the development of cancer resistance to chemotherapeutic regimens and speculate on the molecular mechanisms that might mediate such important feature.

Indexed as

Drug Resistance, NeoplasmAnimalsDiscoidin Domain Receptor 1HumansMutationNeoplasmsReceptor, InsulinDiscoidin Domain Receptor 1Receptor, InsulincancerchemoresistanceDiscoidin Domain Receptor 1receptor crosstalkRTK signalling

Identifiers

PMID29505315
PMCPMC6363036
OpenAlexW2789761739

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.